Hello my dears,
as the stock exchange is open between the years. I am also on the lookout for you during this time.
Since my last presentations of biotech stocks were very successful.
I have continued to dive into this sector for you.
And I have found $MIRM (-0,05%) Mirum.
Anyone who knows me knows that I only invest in profitable companies.
But since I expect Mirum to be profitable next year, I'm already thinking about putting my foot in the door here.
What do you think of my idea of putting my foot in the door here?
And is Mirum the top pick for you "between the years"?
@Multibagger
@All-in-or-nothing
In 2026 a revaluation is possible for Mirum Pharmaceuticals - share with breakout to all-time high!
Von A. Haslinger - Updated on 23.12.25 11:28
I first presented Mirum Pharmaceuticals in the Tenbagger forum in 2023 at a price of USD 28. Since then, the share has performed magnificently and is trading at an all-time high of USD 80. The company focuses on the development and commercialization of therapies for chronic liver diseases.
The company is impressing with strong sales growth, with the main driver being Livmarli, which recently grew by 56 % YoY. It is the only drug in the US approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) aged three months and older.
In 2026, there could be four new drug registrations, including additional indications for Livmarli. This could create revaluation potential for the share in the new year. The share broke out to a new all-time high on December 22 and could now start to follow the trend. (MIRM)
Mirum Pharmaceuticals: From innovator for rare liver diseases to coveted takeover candidate
Mirum Pharmaceuticals - specialist for rare liver diseases with a strong pipeline
- Mirum Pharmaceuticals develops therapies for rare liver diseases with a focus on the regulation of bile acid.
- Key products include Livmarli, Cholbam and Chenodal, with Chenodal having recently completed Phase 3 trials for CTX.
EQS-News: Mirum Pharmaceuticals acquires HBM portfolio company Bluejay Therapeutics for up to USD 820 million
Forecast: This stock is up almost 70% in 2025 and will be an even bigger winner in 2026
- Mirum Pharmaceuticals was a big winner in 2025 thanks to the success of its flagship product Livmarli.
- Livmarli should continue to gain momentum in 2026.
- Good news from a Phase 2 trial of volixibate for the treatment of primary sclerosing cholangitis could also be a catalyst for Mirum next year.
Behind Mirum's meteoric rise
1 Approved in the following regions:
- U.S. - For cholestatic pruritus in patients with ALGS three months of age and older;available in both oral solution and tablet formulations
- E.U. - For cholestatic pruritus in patients with ALGS two months of age and older
- Canada - For cholestatic pruritus in patients with ALGS
Pediatrics (12 months to 18 years): Based on data submitted and reviewed by Health Canada, the safety and effectiveness of LIVMARLI were established in these pediatric patients. Therefore, Health Canada has approved an indication for pediatric use.
Pediatrics (<12 months): The safety and efficacy of LIVMARLI in these pediatric patients have not yet been established.
2 Approved in the following regions:
- USA - For cholestatic pruritus in patients with PFIC 12 months of age and older;available in both oral solution and tablet formulations
- E.U. - For the treatment of PFIC in patients three months of age and older
3 CTEXLI (chenodiol) tablets have been approved by the FDA for the treatment of adults with cerebrotendinous xanthomatosis (CTX)
4 PBD-ZSD = peroxisome biogenesis disorder - cellular pathway spectrum disorder
5 Blinded interim analysis of the VITAS study announced in the PSC on June 17, 2024; the study will continue as planned
6 Interim data from the Phase 2b VANTAGE study investigating the safety and efficacy of volixibate for the treatment of PBC announced on June 17, 2024
Mirum Pharmaceuticals: Transforming Lives in Rare Disease
How did Mirum Pharmaceuticals shares perform?
Current year +91.68%
2024 +40,07%
2023 +51,38%
2022 +22,26%
USD in millions
Estimates
Year
Turnover
Change in
2024 336,9 80,76 %
2025 507,9 50,76 %
2026 596 17,34 %
2027 699,6 17,4 %
Year
EBIT
Change in
2024 -87,61 17,85 %
2025 -19,03 78,28 %
2026 -16,32 14,2 %
2027 33,85 307,36 %
2028 147,83
2029 341,37
Year
Net result
Change in
2024 -87,94 45,35 %
2025 -20,65 76,52 %
2026 -19,68 4,71 %
2027 26,81 236,27 %
2028 120,93
2029 280,79
Year
Net debt
CAPEX
2024 85,6 0,993
2025 -202 0,5215
2026 -212 2
2027 -315 2
Year
Free cash flow
Change in
2024 9,332 113,13 %
2025 46,33 396,5 %
2026 37,67 -18,71 %
2027 104 176,11 %
Year
EBIT margin
ROE
2024 -25,8 % -37,08 %
2025 -3,68 % -8,94 %
2026 -5,56 % -5,11 %
2027 2,87 % 4,11 %
Year
Earnings per share
2024 -1,85
2025 -0,378
2026 -0,4125
2027 0,43
2028 1,72
2029 3,65
No. of shares (in thousands) 51,394
Market value 4,073
Year
P/E RATIO
2024 -22,4x
2025 -210x
2026 -192x
2027 184x
2028 45,96
2029 21,72
